Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-23-037830
Filing Date
2023-06-16
Accepted
2023-06-16 16:17:27
Documents
2
Period of Report
2023-06-14

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4159
2 POA DOCUMENT poa.txt EX-24 2033
  Complete submission text file 0001209191-23-037830.txt   7630
Mailing Address C/O TETRAPHASE PHARMACEUTICALS, INC. 480 ARSENAL STREET, SUITE 110 WATERTOWN MA 02472
Business Address
Lubner David Charles (Reporting) CIK: 0001572000 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41259 | Film No.: 231021370

Mailing Address 25 WEST WATKINS MILL ROAD SUITE A GAITHERSBURG MD 20878
Business Address 25 WEST WATKINS MILL ROAD SUITE A GAITHERSBURG MD 20878 240-723-6641
Arcellx, Inc. (Issuer) CIK: 0001786205 (see all company filings)

EIN.: 472855917 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)